

# **Undernutrition and Risk of Tuberculosis: Updated Meta-Analysis**


Peter Cegielski, MD, MPH

Senior Scientist, Emory Tuberculosis Center

Department of Epidemiology, Rollins School of Public Health

Emory University, Atlanta, Georgia, USA

# Lönnroth 2010: A consistent log-linear relationship between tuberculosis incidence and body mass index




## Lönnroth et al. 2010 summarized 6 studies

|                       |                  |                        |  |
|-----------------------|------------------|------------------------|--|
| <b>Palmer 1957</b>    | <b>USA</b>       | <b>1949 to 1951</b>    | <b>68 754 white, male Navy recruits, 17-21y</b>  |
| <b>Edwards 1971</b>   | <b>USA</b>       | <b>1958 to 1969</b>    | <b>823 199 white male Navy recruits, 17-21y</b>  |
| <b>Tverdal 1986</b>   | <b>Norway</b>    | <b>1963-75 to 1982</b> | <b>Nationally representative sample of 1 7171 695 Norwegians, &gt;14y (compulsory MMR)</b> |
| <b>Cegielski 2012</b> | <b>USA</b>       | <b>1971-75 to 1992</b> | <b>Nationally representative sample of 14 407 adults aged &gt;24y in the USA (NHANES)</b>  |
| <b>Hemilä 1999</b>    | <b>Finland</b>   | <b>1985 to 1993</b>    | <b>26 975 male smokers, 50-69y, in RCT of vit. E</b>                                       |
| <b>Leung 2007</b>     | <b>Hong Kong</b> | <b>2000 to 2005</b>    | <b>42 116 elderly (65y+) in national Elderly Health Service</b>                            |

# Reasons for this updated meta-analysis

1. No studies included HIV infection, no children
2. All six studies in high income countries
3. Three studies only men (US Navy recruits, Finnish smokers)
4. Only two population-based representative samples (USA, Norway)
5. One study pop-based, but only elderly Chinese (Great Famine, 1959-1961)
6. Three did not control for confounding
7. *Only 2 studies had data for BMI<18.5; these 2 differed 10x in incidence rates (USA adults, Hong Kong elderly) → evidence in BMI <18.5 sparse*

**Only two studies in Lönnroth 2010  
included people with BMI < 18.5 kg/m<sup>2</sup>**



gray, Leung

green, Cegielski

# Preview

- ✓ Review 6 studies in Lönnroth et al
- ✓ Motivation behind updated meta-analysis
- ❑ New studies of BMI and TB
- ❑ IPD meta-analysis on vitamin D that also examined BMI
- ❑ Summary of studies
- ❑ Annexes: Summary of studies in PLWH , study details, search strategy

## Six new studies on low BMI and TB incidence

|                              |                  |                             |  |
|------------------------------|------------------|-----------------------------|--|
| <b>Ackley 2015</b>           | <b>1885-1940</b> | <b>Canada First Nations</b> | <b>First Nations native population (~2800) of W. Canada during and after relocation to reservations f/b severe famine late 1890s, followed through 1940</b>        |
| <b>Moran-Mendoza 2010</b>    | <b>1990-2000</b> | <b>Canada</b>               | <b>33 146 HH contacts of TB cases province-wide in British Columbia; median 6y f-u</b>   |
| <b>Park 2022</b>             | <b>2006-2017</b> | <b>Republic of Korea</b>    | <b>2 396 434 adults covered by National Health Examination with 4 consecutive annual evaluations; avg 7.3 years f-u</b>  |
| <b>Aibana 2017</b>           | <b>2009-2012</b> | <b>Peru</b>                 | <b>Among 6 685 HH contacts of active TB cases in shanty towns around Lima, 704 matched controls selected for 180 cases studies of vitamins A, D, E; 1 year f-u</b> |
| <b>Cho 2022</b>              | <b>2010-2017</b> | <b>R. Korea</b>             | <b>11 135 332 adults who participated in 2010 national health screening program (national mandatory annual health insurance examination)</b>                       |
| <b>Jurcev-Savicevic 2013</b> | <b>2006-2008</b> | <b>Croatia</b>              | <b>300 TB cases and 300 matched controls selected from national TB database and general practitioner database</b>  |

|                                |                  |   |  |  |
|--------------------------------|------------------|---|--|--|
| <b>W. Canada First Nations</b> | <b>1885-1940</b> | <b>First Nations native Canadians exposed to severe famine and forced relocation</b>                                      | <b>Increased risk of rapid progression after infection</b>   | <b>aHR=5.4 (4.4, 9.9)</b>  |
| <b>Canada</b>                  | <b>1990-2000</b> | <b>33 146 HH contacts of TB cases province-wide in British Columbia</b>   | <b>Clinical diagnosis of malnutrition</b>  | <b>aHR=37 (13, 111)</b>  |
| <b>Republic of Korea</b>       | <b>2006-2017</b> | <b>2 396 434 adults having National Health Examination, 4 consecutive annual exams</b>                                    | <b>Incidence/10<sup>5</sup> by years underwt.</b><br>0: 51<br>1: 95<br>4: 130  | <b><u>aHR</u></b><br><b>1 (ref)</b><br><b>2.2 (1.9,2.5)</b><br><b>3.3 (3.0, 3.6)</b>                             |
| <b>Peru</b>                    | <b>2009-2012</b> | <b>6 685 HH contacts of active TB in shanty towns around Lima</b>   | <b>180 cases, 704 matched controls</b>   | <b>aHR=4.2 (1.3, 12.9)</b>   |
| <b>R. Korea</b>                | <b>2010-2017</b> | <b>11 135 332 adults in National Health Screening program, 2010, and mandatory annual national health insurance exam.</b> | <b>BMI</b> <b>cIR/10<sup>3</sup></b><br><b>&lt;16.0: 3.3</b><br><b>16 to &lt;17: 2.1</b><br><b>17 to &lt;18.5: 1.6</b><br><b>18.5 to 23: ref</b> | <b><u>aHR</u></b><br><b>2.8 (2.5, 3.1)</b><br><b>2.5 (2.3, 2.7)</b><br><b>2.0 (1.8, 2.2)</b><br><b>1.0 (ref)</b> |
| <b>Croatia</b>                 | <b>2006-2008</b> | <b>300 TB cases and 300 matched controls represent geographically ½ of Croatia</b>  | <b>300 Cases and 300 controls</b>  | <b>aOR=13.6 (1.2, 152)</b>   |



# Individual patient data meta-analysis of 7 studies of vitamin D that also reported BMI (Aibana 2019)

|                                |                      |                                      |                  |
|--------------------------------|----------------------|--------------------------------------|------------------|
| N=3 544 total<br>HIV+ and HIV- | BMI underwt          | <u>aRR (95%CL)</u><br>1.4 (0.9, 1.9) | <u>P</u><br>0.09 |
|                                | BMI overwt           | 0.4 (0.3, -0.6)                      | <0.001           |
| n=456 who<br>developed TB      | <u>Among HIV-neg</u> | <u>aRR (95%CL)</u>                   |                  |
|                                | BMI underwt          | 4.0 (1.8, 8.9)                       | 0.001            |
|                                | BMI overwt           | 0.4 (0.3, 0.6)                       | <0.001           |

| LONNROTH                |  | Summary of ratio measures of effect      |   | NEW EVIDENCE                       |                                  |
|-------------------------|--|--|---|------------------------------------|----------------------------------|
| Palmer 1957             | Wt >15% low (BMI<19.2)                 | cRR=2.5<br>TST+ cRR=2.7                  | <del>5.4 (4.4, 9.2) increase in rapid progression to dz</del> | Famine                             | <del>Ackley 2015</del>           |
| Edwards 1971            | Wt<10% low (BMI <19.6)                 | cRR=1.7<br>TST+: cRR=1.5                 | aHR=37.5 (12.6, 111.4)  | Clinical dx malnutrition           | Moran-Mendoza 2010               |
| <del>Tverdal 1986</del> | <del>BMI&lt;21</del><br>Male<br>Female | <del>cRR=2.3</del><br><del>cRR=1.7</del> | aHR=2.2 (1.9,2.5),<br>aHR=3.3 (3.0, 3.6)                      | BMI<18.5<br>1y<br>4y               | Park 2022                        |
| Cegielski 2012          | BMI <18.5                              | aHR=12.4 (6.5, 27.5)                     | 2.8 (2.5,3.1),<br>2.5 (2.3,2.7),<br>2.0 (1.8,2.0)             | BMI<16<br>BMI 16-17<br>BMI 17-18.5 | Cho 2022                         |
| <del>Hemilä 1999</del>  | <del>BMI&lt;23:</del>                  | <del>aRR=0.5 (0.3,0.7)</del>             | aHR=4.2 (1.3,12.9)  | BMI<18.5                           | Aibana 2017                      |
| Leung 2007              | BMI<18.5:                              | aHR=2.1 (1.6,2.8)                        | aHR=4.0 (1.8, 8.9)  | BMI<18.5, HIV(-),                  | Aibana 2019                      |
|                         |  |  | <del>aOR=13.6 (1.2, 152)</del>                                | <del>BMI&lt;18.5 last year</del>   | <del>2013 Jurcev-Savicevic</del> |

| <b>Study</b>          | <b>Exposure</b>                    | <b>Ratio measures</b>                        | <b>n TB</b>   | <b>N</b>          |
|-----------------------|------------------------------------|--|---------------|-------------------|
| <b>Cho 2022</b>       | <b>BMI &lt;16, 16-17, 17-18.5</b>  | <b>aHR = 2.8, 2.5, 2.0: wtd avg 2.6</b>      | <b>52 615</b> | <b>11 135 332</b> |
| <b>Park 2022</b>      | <b>1, 2, 3, 4 yr. BMI&lt;18.5</b>  | <b>aHR = 2.2, 2.8, 2.7, 3.3: wtd avg 2.7</b> | <b>9322</b>   | <b>2 396 434</b>  |
| <b>Leung 2007</b>     | <b>BMI&lt;18.5</b>                 | <b>aHR = 2.1 (1.6, 2.8)</b>                  | <b>477</b>    | <b>42 116</b>     |
| <b>Aibana 2019</b>    | <b>BMI&lt;18.5 HIV(-),</b>         | <b>aHR = 4.0 (1.8, 8.9)</b>                  | <b>456</b>    | <b>3544</b>       |
| <b>Edwards 1971</b>   | <b>Wt&lt;10% low ~BMI&lt;19.6</b>  | <b>cRR = 1.7 (TST+: cRR = 1.5)</b>           | <b>383</b>    | <b>823 199</b>    |
| <b>Moran-M. 2010</b>  | <b>Clinical dx malnutrition</b>    | <b>aHR = 37.5 (12.6, 111.4)</b>              | <b>228</b>    | <b>33 146</b>     |
| <b>Aibana 2017</b>    | <b>BMI&lt;18.5</b>                 | <b>aHR = 4.2 (1.3, 12.9)</b>                 | <b>180</b>    | <b>6685</b>       |
| <b>Palmer 1957</b>    | <b>Wt &gt;15% low ~BMI&lt;19.2</b> | <b>cRR = 2.5 (TST+ cRR = 2.7)</b>            | <b>109</b>    | <b>68 754</b>     |
| <b>Cegielski 2012</b> | <b>BMI&lt;18.5</b>                 | <b>aHR = 12.4 (5.7, 26.9)</b>                | <b>61</b>     | <b>14 189</b>     |

| <b>Study</b>   | <b>Exposure</b>          | <b>Ratio measures of effect</b>              | <b>n TB</b>   | <b>N</b>          |
|----------------|--------------------------|--|---------------|-------------------|
| Cho 2022       | BMI <16, 16-17, 17-18.5  | aHR = <b>2.8, 2.5, 2.0: wtd avg 2.6</b>      | <b>52 615</b> | <b>11 135 332</b> |
| Park 2022      | 1, 2, 3, 4 yr. BMI<18.5  | aHR = <b>2.2, 2.8, 2.7, 3.3: wtd avg 2.7</b> | <b>9322</b>   | <b>2 396 434</b>  |
| Leung 2007     | BMI<18.5                 | aHR = <b>2.1 (1.6, 2.8)</b>                  | <b>477</b>    | <b>42 116</b>     |
| Aibana 2019    | BMI<18.5 <b>HIV(-),</b>  | aHR = <b>4.0 (1.8, 8.9)</b>                  | <b>456</b>    | <b>3544</b>       |
| Edwards 1971   | Wt<10% low ~BMI<19.6     | cRR = <b>1.7</b> (TST+: cRR = <b>1.5</b> )   | <b>383</b>    | <b>823 199</b>    |
| Moran-M. 2010  | Clinical dx malnutrition | aHR = <b>37.5 (12.6, 111.4)</b>              | <b>228</b>    | <b>33 146</b>     |
| Aibana 2017    | BMI<18.5                 | aHR = <b>4.2 (1.3, 12.9)</b>                 | <b>180</b>    | <b>6685</b>       |
| Palmer 1957    | Wt >15% low ~BMI<19.2    | cRR = <b>2.5</b> (TST+ cRR = <b>2.7</b> )    | <b>109</b>    | <b>68 754</b>     |
| Cegielski 2012 | BMI<18.5                 | aHR = <b>12.4 (5.7, 26.9)</b>                | <b>61</b>     | <b>14 189</b>     |

**Case-weighted average**

**S. Korea: 2.6; Other countries: 7.1**

**Random Effects Model (Saunders et al.)**

**IRR 4.0 (2.0, 8.2)**

# Undernutrition and TB incidence in people living with HIV

## 10 Original studies + 1 SRMA on low BMI and TB incidence in PLWH\* (\*IPT)

|                      |   |  |
|----------------------|---|--|
| Thailand, 1996-2020  | Long term cohort study of 2636 PLWH aged 18+ starting ART from 1996 to 2020; median 7.6 y f-u             | aHR=8.2 (2.4, 27.7)  |
| Tanzania, 2001-08    | 979 HIV+ adults >18y placebo recipients in placebo-controlled randomized TB vaccine trial; mean 3.2 y f-u | <u>per 5 kg/m<sup>2</sup></u><br>BL BMI: aHR=1.4 (1.1,1.7)<br>Delta BMI: aHR=3.2 (2.0,5.5)<br><u>BMI &lt; 17:</u> aHR=3.7 (1.2, 12.) |
| Haiti, 2005-08       | 773 HIV+ adults, CD4<350, free of TB, screened with TST, followed by IPT; 61 TB cases , 251 controls      | cRR*=2.0 (* calc from pub)   |
| South Africa 2003-08 | Prospective clinical cohort study of 3456 PLWH aged 18+;  | aHR 1.6 (1.1, 2.3)   |
| Cambodia 2003-10     | Retrospective analysis of program and medical records for 2984 adults starting ART; 2.4 y f-u             | 1.6 (1.1-2.2)<br>2.4 (1.1–5.0)   |

## **10 Original studies + 1 SRMA on low BMI and TB incidence in PLWH\* (\*many with IPT)**

|  |  |  |
|--|--|--|
| <b>Cambodia 2003-10</b>                          | <b>Retrospective analysis of program and medical records for 2984 adults starting ART; 2.4 y f-u</b>                       | <b>1.6 (1.1-2.2)<br/>2.4 (1.1–5.0)</b>                                     |
| <b>Tanzania 2011-14</b>                          | <b>Retrospective cohort study of IPT for reducing TB incidence in PLWH receiving care and treatment services, n=68 378</b> | <b>aHR = 1.7 ( 1.5–1.9)<br/>aHR = 1.8 (1.5–2.1)</b>                        |
| <b>Ethiopia 2013-17</b>                          | <b>633 HIV+ children&lt;14y starting ART in HIV care at one referral hospital; median 32 months f-u</b>                    | <b>WAZ &lt;-2: aHR: 5.2 (1.9, 14.2)<br/>WHZ &lt;-2: aHR 2.9 (1.0, 8.0)</b> |
| <b>Uganda, Tanzania, Kenya, Nigeria, 2013-21</b> | <b>Longitudinal cohort study of 3171 PLHIV aged 15+</b>  | <b>2.3 (1.3, 4.0)</b>  |
| <b>Ethiopia, 2020</b>                            | <b>Retro. cohort study of 539/2168 patients receiving ART during universal test and treat program</b>                      | <b>2.4 (1.3, 4.5)</b>  |
| <b>Sub-Saharan Africa 2000-22</b>                | <b>SRMA of 43 studies of TB incidence and risk factors in PLHIV</b>  | <b>1.8 (1.6, 2.0)</b>  |

*Thank you for your attention!*



Details of studies presented

# Palmer et al. and Edwards et al., Two US Navy Studies

| Study population  | Nutritional status            | TB incidence/100 <sup>5</sup> /y | Ratio             |
|---|-------------------------------|----------------------------------|-------------------|
| <p>N=68 754 white, male Navy recruits, age 17-21, 1949-51 followed for 4 years (IQR 3.4-5.3); <b>N=109 TB cases</b></p> | <p><u>%med Wt4Ht BMI:</u></p> | <p><u>TST- TST+ All</u></p>      | <p><u>cRR</u></p> |
|   | <p>≥15 below ≤19.2</p>        | <p>51 264 75.1</p>               | <p>2.5</p>        |
|   | <p>5-14 below 19.3-21.5</p>   | <p>34 214 48.5</p>               | <p>1.5</p>        |
|   | <p>Within 4.9 21.6-23.7</p>   | <p>20 110 29.7</p>               | <p>1(ref)</p>     |
|   | <p>≥5% above ≥23.7</p>        | <p>16 70 18.9</p>                | <p>0.6</p>        |
| <p>823 199 white male Navy recruits aged 17-21, 1958-1969, followed for 4 years (range 2-12); <b>383 TB cases</b></p>   | <p><u>%med Wt4Ht BMI:</u></p> | <p><u>TST- TST+ ALL</u></p>      | <p><u>cRR</u></p> |
|   | <p>≥10% below ≤19.6</p>       | <p>59 609 170</p>                | <p>1.7</p>        |
|   | <p>Within 9.9% 19.7-23.9</p>  | <p>33 407 100</p>                | <p>1(ref)</p>     |
|   | <p>≥10% above &gt;23.9</p>    | <p>17 178 48</p>                 | <p>0.5</p>        |

## Tverdal and Cegielski et al., Two Population-based Studies

| Study population  | Nutritional status | TB incidence /100 <sup>5</sup> /y | Ratio              |
|---|--------------------|-----------------------------------|--------------------|
| <b>1 717 695 Norwegians aged &gt;14 years participating in compulsory mass miniature radiography, 1963-75, followed for 8-19 years;</b><br><b>2531 TB cases</b> | <u>BMI</u>         | <u>Male Female</u>                | <u>Male Female</u> |
|   | <21                | 294 123                           | 2.3 1.7            |
|   | 21-24.9            | 129 72                            | 1 (ref)            |
|   | 25-28.9            | 72 48                             | 0.6 0.7            |
|   | >29                | 41 25                             | 0.3 0.3            |
| <b>14 189 NHANES-1 nationally representative sample of U.S. adults, 1971-75, followed for 17-21 years;</b> <b>61 TB cases</b>                                   | <u>&lt;BMI</u>     | <u>Pop'n TB incidence</u>         |                    |
|   | 18.5               | 260 (99, 422)                     | 12 (6, 27)         |
|   | 18.5-25            | 25 (13, 36)                       | 1 (ref)            |
|   | 25-30              | 9 (2, 16)                         | 0.3 (.1,.6)        |
|   | >30                | 5 (0, 10)                         | 0.2 (.1,.6)        |

# Hemilä et al., male smokers in unrelated RCT Leung et al., population-based sample of elderly

| Study population  | Nutrition   | TB/100 <sup>5</sup> /y                                   | Ratio  |
|---|---|--|--|
| <p>26 975 Finnish male smokers aged 50-69 in RCT of vit. E for cancer prevention, 1985-93, followed for 6.1 y (5-8y);<br/><b>197 TB cases</b></p> | <p><u>BMI</u><br/>&lt;23:<br/>23-27:<br/>&gt;27:</p>                        | <p><u>TB/100k</u><br/>192<br/>92<br/>55</p>              | <p><u>aHR</u><br/>1.0 (ref)<br/>0.5 (0.3,0.7)<br/>0.3 (0.2,0.4)</p>                      |
| <p>42 116 Hong Kong Chinese elderly aged 65+ in national Elderly Health Service, 2000-05 followed for 5y (+/-0.9);<br/><b>477 TB cases</b></p>    | <p><u>Total</u><br/>&lt;18.5<br/>18.5-23<br/>23-25<br/>25-30<br/>&gt;30</p> | <p><u>226</u><br/>732<br/>291<br/>200<br/>148<br/>82</p> | <p>2.1 (1.6,2.8)<br/>1.0 (ref)<br/>0.7 (0.6,0.9)<br/>0.6 (0.5,0.7)<br/>0.4 (0.2,0.7)</p> |

# Two new studies of BMI from Western Canada

|   |  |  |
|---|--|--|
| 1885-1940<br>W. Canada<br>First Nations | Epidemic model of TB before/ during/ after 1890s famine coinciding with relocation to reservations; Time-varying parameters for<br>1) increased prob. infection,<br>2) increased prob. rapid progression (innate immunity vs. adaptive immunity) | Only one famine specific parameter, <b>5.4-fold (4.4, 9.2) increase in risk of rapid progression</b> , best accounted for spike in TB, not risk of infection |
| 1990-2000<br>Canada                     | British Columbia province wide population, 33 146 HH contacts (of 3485 TB cases) (excluding HIV+) followed for 6 y (0-12); <b>228 TB cases (668/10<sup>5</sup>)</b>  | Clinical diagnosis malnutrition increased risk of TB:<br><b>cHR = 28.5 (11.7, 69.3),<br/>aHR = 37.5 (12.6, 111.4)</b>  |

## Two new studies of BMI: HH contacts cohort in Peru, TB Case-control comparison in Croatia

|                          |   |  |
|--------------------------|---|--|
| Croatia<br>2005-<br>2008 | Case control study of 300 lab-confirmed TB patients and 300 matched controls, population representative sampling; only 2 controls and 10 cases underweight in previous year   | cOR=10.0 (2.1, 47.8)<br>aOR=13.6 (1.2,152)                                   |
| Peru<br>2009-<br>2012    | Case-control study nested in prospective cohort of 6685 HH contacts of TB patients in Lima shanty towns followed at 2, 6, 12 mo;<br><b>180 TB cases</b> diagnosed >90 d. after blood sample matched to 704 controls | BMI<18.5: aHR=4.2 (1.3, 12.9)<br>Normal: 1.0 (ref)<br>BMI>25: 0.4 (0.3, 0.6) |

# Two new population-bases studies from R. Korea based on national health insurance annual examination

| <p>Republic of Korea, 2006-2017</p> | <p>Population cohort of 2 396 434 adults with serial National Health Exams, followed for mean 7.3 years examining number of years (0-4) person was underweight; <b>9322 TB cases total</b>, (8150 among 2.25m with no underweight).</p> | <table border="1"> <thead> <tr> <th>Y</th> <th>n /10<sup>5</sup></th> <th>aHR (CL)</th> </tr> </thead> <tbody> <tr> <td>0:</td> <td>50.8</td> <td>ref</td> </tr> <tr> <td>1:</td> <td>94.6</td> <td>2.2 (1.9,2.5)</td> </tr> <tr> <td>2:</td> <td>115</td> <td>2.8 (2.5, 3.2)</td> </tr> <tr> <td>3:</td> <td>109</td> <td>2.7 (2.4, 3.2)</td> </tr> <tr> <td>4:</td> <td>130</td> <td>3.3 (3.0, 3.6)</td> </tr> </tbody> </table> | Y   | n /10 <sup>5</sup> | aHR (CL) | 0:     | 50.8 | ref            | 1:         | 94.6 | 2.2 (1.9,2.5)  | 2:           | 115 | 2.8 (2.5, 3.2) | 3:          | 109 | 2.7 (2.4, 3.2) | 4: | 130 | 3.3 (3.0, 3.6) |
|-------------------------------------|---|--|-----|--------------------|----------|--------|------|----------------|------------|------|----------------|--------------|-----|----------------|-------------|-----|----------------|----|-----|----------------|
| Y                                   | n /10 <sup>5</sup>  | aHR (CL)   |     |                    |          |        |      |                |            |      |                |              |     |                |             |     |                |    |     |                |
| 0:                                  | 50.8  | ref  |     |                    |          |        |      |                |            |      |                |              |     |                |             |     |                |    |     |                |
| 1:                                  | 94.6  | 2.2 (1.9,2.5)  |     |                    |          |        |      |                |            |      |                |              |     |                |             |     |                |    |     |                |
| 2:                                  | 115   | 2.8 (2.5, 3.2)   |     |                    |          |        |      |                |            |      |                |              |     |                |             |     |                |    |     |                |
| 3:                                  | 109   | 2.7 (2.4, 3.2)   |     |                    |          |        |      |                |            |      |                |              |     |                |             |     |                |    |     |                |
| 4:                                  | 130   | 3.3 (3.0, 3.6)   |     |                    |          |        |      |                |            |      |                |              |     |                |             |     |                |    |     |                |
| <p>R. Korea, 2010-2017</p>          | <p>Population cohort of 11 135 332 from annual National Health Insurance Examination who participated in 2010 health screening program, <b>52 615 TB cases</b> over 7 years</p>   | <table border="1"> <thead> <tr> <th>BMI</th> <th>/10<sup>3</sup></th> <th>aHR (CL)</th> </tr> </thead> <tbody> <tr> <td>&lt;16.0:</td> <td>3.3</td> <td>2.8 (2.5, 3.1)</td> </tr> <tr> <td>16 to &lt;17:</td> <td>2.1</td> <td>2.5 (2.3, 2.7)</td> </tr> <tr> <td>17 to &lt;18.5:</td> <td>1.6</td> <td>2.0 (1.8, 2.2)</td> </tr> <tr> <td>18.5 to 23:</td> <td>1.0</td> <td>1.0 (ref)</td> </tr> </tbody> </table>                | BMI | /10 <sup>3</sup>   | aHR (CL) | <16.0: | 3.3  | 2.8 (2.5, 3.1) | 16 to <17: | 2.1  | 2.5 (2.3, 2.7) | 17 to <18.5: | 1.6 | 2.0 (1.8, 2.2) | 18.5 to 23: | 1.0 | 1.0 (ref)      |    |     |                |
| BMI                                 | /10 <sup>3</sup>  | aHR (CL)   |     |                    |          |        |      |                |            |      |                |              |     |                |             |     |                |    |     |                |
| <16.0:                              | 3.3   | 2.8 (2.5, 3.1)   |     |                    |          |        |      |                |            |      |                |              |     |                |             |     |                |    |     |                |
| 16 to <17:                          | 2.1   | 2.5 (2.3, 2.7)   |     |                    |          |        |      |                |            |      |                |              |     |                |             |     |                |    |     |                |
| 17 to <18.5:                        | 1.6   | 2.0 (1.8, 2.2)   |     |                    |          |        |      |                |            |      |                |              |     |                |             |     |                |    |     |                |
| 18.5 to 23:                         | 1.0   | 1.0 (ref)  |     |                    |          |        |      |                |            |      |                |              |     |                |             |     |                |    |     |                |

## Four original studies + 1 SRMA on low BMI and TB incidence in people with HIV

|                                       |                                  |  |                 |
|---------------------------------------|----------------------------------|--|-----------------|
| Retrospective cohort of 451 PLWH      | Ethiopia                         | N cases<br>8.6 TB/100py x 1377 py      | 2.5 (1.3, 5.1)  |
| Longitudinal cohort of 3171 PLHIV     | Uganda, Tanzania, Kenya, Nigeria | 79/13161 py<br>(600/100k?)             | 2.3 (1.3, 4.0)  |
| Long term cohort study of 2636 PLWH   | Thailand                         | 113 TB cases,<br>4.7/1000py (3.9, 5.6) | 8.2 (2.4, 27.7) |
| Retrospective cohort of 539/2168 PLWH | Ethiopia                         | 74 TB cases<br>4.8/100py               | 2.4 (1.3, 4.5)  |
| SRMA of 43 studies                    | Sub-Saharan Africa               | 3.4/100py adults<br>3.8/100py children | 1.8 (1.6, 2.0)  |



# Five original studies on low BMI and TB incidence in people with HIV

|   |              |   |   |
|---|--------------|---|---|
| 979 adults, placebo recipients in TB vaccine RCT          | Tanzania     | 92 cases x 3.2 years f-u  | <u>per 5 kg/m<sup>2</sup> decrease (~1 category)</u><br>Baseline BMI: aHR=1.4 (1.1,1.7)<br>Yr. 1 BMI: aHR=1.7 (1.3,2.4)<br>Change BMI: aHR=3.2 (2.0,5.5)<br><u>BMI &lt; 17</u><br>All subjects: aHR=3.7 (1.2, 12.0)<br>TST-neg: aHR=6.1 (1.5, 25.4) |
| 633 HIV+ children   | Ethiopia     | 67 incident TB cases, 32 mo f-u;<br>6/100 p-y before ART,<br>2.3/100 p-y while on ART | WAZ <-2: aHR: 5.2 (1.9, 14.2)<br>WHZ <-2: aHR 2.9 (1.0, 8.0)  |
| Retrospective cohort of 68 378 PLWH in care and treatment | Tanzania     | 3124 TB cases in 114 926 py fu =<br>2.7/100py (2.6, 2.8)                              | aHR = 1.7 ( 1.5–1.9)<br>aHR = 1.8 (1.5–2.1)   |
| Retrospective analysis of 2984 adults starting ART        | Cambodia     | 313 (10.5%) = 3.9/100py<br>101/179<br>74/134  | 1.6 (1.1-2.2)<br>2.4 (1.1–5.0)  |
| Prospective clinical cohort study of 3456 PLWH            | South Africa | 226 incident cases = 4.5/100py<br>BMI<18.5: 7.3/100<br>18.5-25: 6.0/100               | aHR 1.6 (1.1, 2.3)  |

# Two new studies of low BMI in PLHIV in Tanzania

|                                      |  |   |
|--------------------------------------|--|---|
| <p><b>2001-2008<br/>Tanzania</b></p> | <p>979 Placebo recipients in “Dar-Dar” randomized controlled TB vaccine trial, <b>HIV+ adults</b> 18+ y.o. followed for 3.2 years;<br/><b>92 incident TB cases total</b></p> | <p><u>Effect per 5 kg/m<sup>2</sup> decrease (~1 category)</u></p> <ul style="list-style-type: none"> <li>• Baseline BMI: aHR=1.4 (1.1,1.7)</li> <li>• Yr. 1 BMI: aHR=1.7 (1.3,2.4)</li> <li>• Change BMI: aHR=3.2 (2.0,5.5)</li> </ul> <p><u>BMI &lt; 17</u></p> <ul style="list-style-type: none"> <li>• All subjects: aHR=3.7 (1.2, 12.0)</li> <li>• TST-neg: aHR=6.1 (1.5, 25.4)</li> </ul> |
| <p><b>Tanzania<br/>2011-2014</b></p> | <p>Retrospective analysis of 68 378 PLWH receiving care and treatment services in DSM followed for 3.4 y;<br/><b>3124 TB cases in 114 926 py fu =</b></p>                    | <p>Incidence rate: 2.7/100py (2.6,2.8)</p> <p>Two aHR reported for BMI&lt;18.5: 1.7 (1.5, 1.9) and 1.8 (1.5-2.1)</p>  |

# Three new studies of low BMI in PLHIV from Ethiopia

|  |  |   |
|--|--|---|
| <p><b>Ethiopia<br/>11/2020</b></p>             | <p>Retrospective cohort study of a SRS of 539 adults among 2168 PLWH receiving ART after universal test and treat program 0.5 to 56.6 mos f-u; <b>74 TB cases</b></p>                | <p>Incidence rate: = 4.8/100py<br/>aHR 2.4 (1.3, 4.5)</p>   |
| <p><b>Ethiopia<br/>2010-2015<br/>Ahmed</b></p> | <p>Retrospective cohort of 451 adults PLWH newly enrolled in HIV care clinic; <b>118 TB cases in 1377 py fu</b></p>  | <p>Incidence 8.6/100 py<br/>aRR 2.5 (1.3, 5.1)</p>  |
| <p><b>2013-2017<br/>Ethiopia</b></p>           | <p>Institution-based, retrospective record review of 633 <b>HIV+ children</b> starting chronic ART (42% IPT) followed for median 32 mo.;<br/><b>67 incident TB cases overall</b></p> | <p>Incidence: 6/100 p-y before ART, 2.3/100 p-y while on ART</p> <ul style="list-style-type: none"> <li>• WAZ &lt;-2: aHR: 5.2 (1.9, 14.2)</li> <li>• WHZ &lt;-2: aHR 2.9 (1.0, 8.0)</li> </ul> |

# Two new studies of low BMI in PLHIV from SE Asia

|                               |   |  |
|-------------------------------|---|--|
| <b>Thailand<br/>1996-2020</b> | Secondary analysis of HIVNET 006 Study cohort, 2636 PLWH aged $\geq 18$ years who started ART 1996-2020; a prospective, clinic-based cohort that has enrolled adults living with HIV aged $\geq 18$ years since 1996; Clinicaltrials.gov NCT00411983. 2636 PLWH x 24 229 py fu, med. 7.6 y (1.9, 15.7); <b>113 TB cases, increasing linearly from 0.7% at 1 year to 4.3% at 7 years</b> | cIR=4.7/1000py (3.9, 5.6)<br><br>For BMI<18.5<br>aSHR=8.2 (2.4, 27.7, p=0.001) |
| <b>Cambodia<br/>2003-2010</b> | Retrospective analysis of 2984 PLWH adults starting ART fu for 2.4 yrs median based on programmatic data and medical records; <b>313 total TB cases = 3.9/100py, early incident TB: 179; late incident TB: 134</b>  | Early: 1.6 (1.1, 2.2)<br>Late: 2.4 (1.1, 5.0)                                  |

# Two new multinational studies of low BMI in PLHIV

|   |   |  |
|---|---|--|
| <b>Uganda, Tanzania, Kenya, Nigeria<br/>2013-2021</b> | Long running longitudinal “AFRICOS” cohort study of 3171 PLWH age 15+ fu for 3.0y (1.4-4.5);<br><b>79 TB cases in 13 161 py fu;</b>             | Incidence 600/100k<br>aHR 2.3 (1.3, 4.1)   |
| <b>SRMA<br/>Studies published<br/>2000-2022</b>       | SRMA of TB incidence and risk factors in PLHV in sub-Saharan Africa: 43 heterogeneous studies with N=212 to 527,000; TB cases from 15 to 22,071 | cIR: 3.5/100py (2.9, 4.2)<br>(range 0.2 to 8.8/100py)<br>aHR: 1.8 (1.6, 2.0)<br>(with no sig. heterogeneity) |

# Study of vitamin A that reported BMI

## Case-cohort studies nested in RCTs of ART in HIV+ adults

|  |   |  |   |
|--|---|--|---|
| <p><b>Podell, 2022</b></p> <p><b>Haiti 2005-08</b></p> | <p><b>773 HIV+ adults,<br/>CD4&lt;350, free of TB,<br/>screened with TST,<br/>followed by IPT;</b></p> <p><b>61 TB cases</b></p> <p><b>251 controls</b></p> | <p><u>61 TB Cases</u></p> <p>Uwt: 15/61 (25.0)</p> <p>Norm: 35/61 (58.3)</p> <p>Owt: 10/61 (16.7)</p> <p><u>Non-cases</u></p> <p>Uwt: 32/251 (12.8)</p> <p>Norm: 182/251 (72.5)</p> <p>Owt 37/251 (14.7)</p> | <p><u>Uwt</u> : RR*=2.0</p> <p><u>Owt</u> : RR*=0.9</p> <p>*Crude RR computed from reported frequencies</p> |
|--|---|--|---|

# Micronutrient studies that reported mean BMI

|                |                         |  |   |
|----------------|-------------------------|--|---|
| Getz HR 1951   | Philadelphia, 1942-1949 | 1100 men, 83% Black, in prospective cohort study of multiple micro-nutrients | No difference in “percent of standard weight” between those who did vs did not develop TB                             |
| Soh AZ, 2017   | Singapore, 1993-2014    | 62 257 Chinese adults<br>1186 incident TB cases                              | <u>BMI Mean :</u><br>Developed TB 22.3 (+/-3.5)<br>Did not: 23.2 (+/-3.2)<br>p<0.01                                   |
| Tenforde, 2017 | 9 Countries, 2005-07    | 1571 HIV+ adults, CD4<300 subjects in “PEARLS” trial, ACTG #A5175            | <u>BMI Mean</u><br>Developed TB: 21.6 (19.5, 22.9)<br>No TB: 22.3 20.1, 25.1).<br>Dif: 0.7 kg/m <sup>2</sup> , p=0.02 |